title: Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.
abstract: Current literature provides conflicting evidence regarding the efficacy of lenalidomide in patients with myelofibrosis (MF). The aim of this work was to evaluate the efficacy of lenalidomide in patients with MF treated within a named patient program in Austria. A total of 22 patients with MF were treated with lenalidomide in 7 different centres throughout Austria. Median age of patients was 68 years. Primary MF was present in 13 patients. Eight patients had post-polycythemia vera (post-PV) and 1 post-essential thrombocythemia (post-ET) MF. According to the Dynamic International Prognostic Scoring System (DIPSS), all patients were scored within the intermediate-2 or high-risk group. Approximately one-third of patients were treated with 2 or more prior therapies. The overall response rate according to International Working Group (IWG) criteria was 12.5 %. Efficacy of lenalidomide was moderate in this non-study patient population. Limiting factors seemed to be stage of disease and risk profile of patients included in this analysis.
authors.affiliation: Innere Medizin IV, Klinikum Wels-Grieskirchen, Grieskirchnerstraße 42, 4600 Wels, Austria. sonja.burgstaller@klinikum-wegr.at
authors.forename: Sonja
authors.initials: S
authors.lastname: Burgstaller
authors.forename: Michael
authors.initials: M
authors.lastname: Fridrik
authors.forename: Sabine
authors.initials: S
authors.lastname: Hojas
authors.forename: Thomas
authors.initials: T
authors.lastname: Kühr
authors.forename: Heinz
authors.initials: H
authors.lastname: Ludwig
authors.forename: Beate
authors.initials: B
authors.lastname: Mayrbäurl
authors.forename: Rainer
authors.initials: R
authors.lastname: Pöhnl
authors.forename: Michael
authors.initials: M
authors.lastname: Pötscher
authors.forename: Ernst
authors.initials: E
authors.lastname: Schlögl
authors.forename: Daniela
authors.initials: D
authors.lastname: Zauner
authors.forename: Josef
authors.initials: J
authors.lastname: Thaler
authors.forename: Heinz
authors.initials: H
authors.lastname: Gisslinger
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000139:chemically induced*; D001317:Austria; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007155:Immunologic Factors; D000077269:Lenalidomide; D007970:Leukopenia / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis; D016896:Treatment Outcome
chemical_list: D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide
references.citation: N Engl J Med. 2012 Mar 1;366(9):787-98
references.pmid: 22375970
references.citation: Blood. 2007 Aug 15;110(4):1092-7
references.pmid: 17488875
references.citation: Blood. 2011 Jul 28;118(4):899-902
references.pmid: 21622644
references.citation: J Clin Oncol. 2009 Oct 1;27(28):4760-6
references.pmid: 19720904
references.citation: Blood. 2006 Sep 1;108(5):1497-503
references.pmid: 16675707
references.citation: Blood Cancer J. 2011 May;1(5):e20
references.pmid: 22829155
references.citation: Blood. 2010 Nov 25;116(22):4436-8
references.pmid: 20651074
references.citation: Blood. 2009 Mar 26;113(13):2895-901
references.pmid: 18988864
references.citation: Cancer J. 2007 Nov-Dec;13(6):377-83
references.pmid: 18032975
references.citation: N Engl J Med. 2012 Mar 1;366(9):799-807
references.pmid: 22375971
references.citation: Blood. 2006 Aug 15;108(4):1158-64
references.pmid: 16609064